FierceBiotech

PRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...
ots

Study Shows Subcutaneous Injection With MIRCERA is Significantly Less Painful Than With SC Aranesp

being a common adverse event and a burden for patients with chronic kidney disease (CKD).
Europa Press

Innovative New Anaemia Drug MIRCERA Demonstrates Ability to Maintain Tight Haemoglobin Levels at Once Monthly Dosing in

-- First Publication of Phase III Data in the Clinical Journal of the American Society of Nephrology Results from a multi-centre renal anaemia study show that switching patients directly from frequent ...
Monthly Prescribing Reference

Mircera Approved to Treat Anemia in Pediatric Patients With CKD

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...
Science Daily

Researchers discover novel method for detecting MIRCERA

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced ...
FierceBiotech

PRESS RELEASE: Mircera approved in European Union for treatment of anaemia related to chronic kidney disease

Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...
PharmaTimes

FDA approves Roche’s anaemia drug Mircera

US regulators have given the green light to Roche's new anaemia drug Mircera, but no launch across the Atlantic is likely for some time as the Swiss firm is embroiled in a legal dispute it is losing ...
WebMD

Subcutaneous Injections

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...
Europa Press

Study Shows Subcutaneous Injection With MIRCERA is Significantly Less Painful Than With SC Aranesp (y 2)

(4) For patients not currently treated with an erythropoiesis stimulating agent (ESA), the recommended starting dose is 0.6 microgram/kg body weight, administered once every two weeks as a single ...
Medindia

FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing

NUTLEY, N.J., Nov. 14 Roche announced today that the U.S. Food and Drug Administration (FDA) has approved MIRCERA (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia associated with ...
ots

Innovative New Anaemia Drug MIRCERA Demonstrates Ability to Maintain Tight Haemoglobin Levels at Once Monthly Dosing in Dialysis Patients With Chronic Kidney Disease

three times a week for the maintenance treatment of anaemia. The study results showed: - Minute changes in patients' haemoglobin (Hb) levels from baseline to evaluation (-0.131g/dL for MIRCERA once ...